JianXin (Beijing)
建信（北京）
JianXin (Beijing) is a fund that appears in elsewhere's corpus primarily as an investor in two deals: it backed Machenike's Series B+ round in 2023 and participated in Haichang Biotech's nearly 500 million yuan Series C round in 2025 . In the latter, it was grouped alongside state-linked and industrial capital as part of what the announcement called a "three-dimensional capital matrix" combining national strategic guidance, local industrial coordination, and supply-chain co-construction . The name "建信投资" suggests ties to China Construction Bank's investment platform, though elsewhere's corpus does not explicitly confirm this affiliation. The fund is distinct from the similarly named JianXin (Beijing) entity that appears in some unrelated background coverage.
AI-generated — may contain errors, please verify.
Coverage
Haichang Biotech Closes Nearly 500 Million Yuan Series C Round to Accelerate Development of Innovative Nucleic Acid Drugs and Complex Injectables
Focused on the R&D and industrial application of drug delivery system technologies.
Year-end good news: CDH Investments has raised 5 billion yuan for logistics investments.
Insurance capital is turning its attention to real estate investments.
Machenike Closes Over 100 Million RMB Series B+ Round | BlueRun Ventures
Building the Next Generation of ADAS Advanced Driver-Assistance Systems
